Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PTPRA | P18433 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | KDM6B | O15054 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10170670 | 1.00 | PPARG (0.51) | PPARGPPARASMN1; SMN2PTPRAALDH1A1 | |
| SCHEMBL8953481 | 1.00 | PPARG (0.51) | PPARGPPARASMN1; SMN2PTPRAALDH1A1 | |
| SCHEMBL3351318 | 1.00 | PPARG (0.51) | PPARGPPARASMN1; SMN2PTPRAALDH1A1 | |
| SCHEMBL1822200 | 1.00 | PPARG (0.51) | PPARGPPARASMN1; SMN2PTPRAALDH1A1 | |
| SCHEMBL16815808 | 0.85 | SMN1; SMN2 (0.44) | PPARGPPARASMN1; SMN2PTPRAKDM6B | |
| SCHEMBL28185307 | 0.85 | SMN1; SMN2 (0.44) | PPARGPPARASMN1; SMN2PTPRAKDM6B | |
| SCHEMBL7274320 | 0.82 | CYP1A2 (0.55) | PPARGPPARAALDH1A1KMT2AMEN1 | |
| SCHEMBL8953483 | 0.81 | PPARG (0.56) | PPARGPPARASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL6443526 | 0.79 | KDM4E (0.51) | PPARGPPARASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL7506333 | 0.79 | PPARG (0.54) | PPARGPPARAALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4558513-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | Merck Sharp & Dohme LLC (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024020159-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2024-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | PPARG 2133/4885PPARA 3452/4885SMN1; SMN2 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.